ReviewInternational journal of antimicrobial agents2011
Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?
Review in International journal of antimicrobial agents, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 298 citations in OpenAlex.
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Truncated Equinin B Variants Reveal the Sequence Determinants of Antimicrobial Selectivity.Marine drugs · 2026Article
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Isolation, Characterization, and Optimization of Antimicrobial Proteinaceous Compounds Produced byInternational journal of microbiology · 2026Article
- Article
- Polyacrylamide-Based Antimicrobial Copolymers to Replace or Rescue Antibiotics.ACS central science · 2025Article
- Design of Natterins-based peptides improves antimicrobial and antiviral activities.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- A Novel Dimeric Short Peptide Derived from α-Defensin-Related Rattusin with Improved Antimicrobial and DNA-Binding Activities.Biomolecules · 2024Article
- New-generation biofilm effective antimicrobial peptides and a real-time anti-biofilm activity assay: CoMIC.Applied microbiology and biotechnology · 2024Article
- The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human PathogenPharmaceuticals (Basel, Switzerland) · 2024Article
- Evaluation of glycyl-arginine and lysyl-aspartic acid dipeptides for their antimicrobial, antibiofilm, and anticancer potentials.Archives of microbiology · 2023Article
- Multifunctional Properties of BMAP-18 and Its Aliphatic Analog against Drug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems.Life (Basel, Switzerland) · 2023Review
- It is the time for quorum sensing inhibition as alternative strategy of antimicrobial therapy.Cell communication and signaling : CCS · 2023Review
- Inorganic hollow mesoporous spheres-based delivery for antimicrobial agents.Frontiers of materials science · 2023Review
- Strategies to Mitigate and Treat Orthopaedic Device-Associated Infections.Antibiotics (Basel, Switzerland) · 2022Review
- Antimicrobial Peptide Octominin-Encapsulated Chitosan Nanoparticles Enhanced Antifungal and Antibacterial Activities.International journal of molecular sciences · 2022Article
- 10-mer and 9-mer WALK Peptides with Both Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial peptide in polymethylmethacrylate bone cement as a prophylaxis of infectious complications in orthopedics-an experiment in a murine model.Folia microbiologica · 2022Article
- Peptide Conjugates Derived from flg15, Pep13, and PIP1 That Are Active against Plant-Pathogenic Bacteria and Trigger Plant Defense Responses.Applied and environmental microbiology · 2022Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The concept of antimicrobial peptides (AMPs) as potent pharmaceuticals is firmly established in the literature, and most research articles on this topic conclude by stating that AMPs represent promising therapeutic agents against bacterial and fungal pathogens. Indeed, early research in this field showed that AMPs were diverse in nature, had high activities with low minimal inhibitory concentrations, had broad spectrums of activity against bacterial, fungal and viral pathogens, and could easily be manipulated to alter their specificities, reduce their cytotoxicities and increase their antimicrobial activities. Unfortunately, commercial development of these peptides, for even the simplest of applications, has been very limited. With some peptides there are obstacles with their manufacture, in vivo efficacy and in vivo retention. More recently, the focus has shifted. Contemporary research now uses a more sophisticated approach to develop AMPs that surmount many of these prior obstacles. AMP mimetics, hybrid AMPs, AMP congeners, cyclotides and stabilised AMPs, AMP conjugates and immobilised AMPs have all emerged with selective or 'targeted' antimicrobial activities, improved retention, or unique abilities that allow them to bind to medical or industrial surfaces. These groups of new peptides have creative medical and industrial application potentials to treat antibiotic-resistant bacterial infections and septic shock, to preserve food or to sanitise surfaces both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.